Compare Hilton Hotels Corporation Common Stock (HLT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Incyte Corporation — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.41 (market cap $70.82B), while Incyte Corporation trades at $120.8 (market cap $24.54B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.9× Incyte Corporation's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HLT | INCY | |
|---|---|---|
Market Cap | $70.82B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $129.93 |
52-Week Low | $256.75 | $81.61 |
Enterprise Value | $83.83B | $20.04B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $322.51, up 3.7% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $12.04B in 2025 and net income of $1.46B. Recent news highlights labor strikes and executive stock sales, while analyst consensus remains bullish with a $352 price target.
HLT offers growth potential from travel recovery and pipeline expansion, but faces risks from premium valuation (P/E 46.21), rising debt levels, and operational challenges. The stock trades near resistance at $316-$319, requiring strong Q3 earnings to sustain momentum amid mixed technical indicators.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
